Home
Anaconda Pharma is a privately held, venture backed, biopharmaceutical company based in Paris, France. Anaconda Pharma has developed a unique and proprietary platform for the discovery of small molecules that disrupt protein:protein interactions. These represent a major new class of pharmaceutical targets that have been unexploited to date due to the difficulty of recognizing drug'able hot-spots on the surface of interacting proteins.
Targeting protein:protein interactions with small drugs
While small molecule drugs classically target enzymes, cellular receptors and ion channels, the majority of biological functions are facilitated by proteins interacting with other proteins. Antagonists of protein:protein interactions that have reached the market include therapeutic antibodies. Antibodies, however, have some drawbacks: high cost of production, lack of oral bioavailability and limited penetration inside of cells - i.e. a capacity to target only extracellular protein:protein interactions.
Anaconda Pharma is targeting protein:protein interactions with small molecules in the antiviral field.
Printable Page
 |
< HOME PAGE | © 2006 Anaconda Pharma |  |